NCT05057182View on ClinicalTrials.gov

Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

March 31, 2024

Study Completion Date

December 31, 2024

Conditions

COVID 19 Vaccine

Interventions

BIOLOGICAL

BNT162b2

BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.

Trial Locations (1)

00000

The University of Hong Kong, Hong Kong

All Listed Sponsors

lead

The University of Hong Kong

OTHER